189 Treatment of chronic hepatitis C with peginterferon ALFA-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response
- 31 December 2003
- journal article
- abstracts
- Published by Elsevier in Hepatology
- Vol. 38, 246
- https://doi.org/10.1016/s0270-9139(03)80232-x
Abstract
No abstract availableThis publication has 0 references indexed in Scilit: